Results 121 to 130 of about 2,404 (154)

Nirsevimab rollout in the Gulf Cooperation Council, scoping review protocol

Protocol for a PRISMA-ScR scoping review of nirsevimab implementation across the six Gulf Cooperation Council countries during the 2024 to 2025 and 2025 to 2026 RSV seasons, with cost-effectiveness modeling for Kuwait, Qatar, Bahrain, and Oman ...
Rabia Shah
core  

Maternal Vaccination vs Nirsevimab Use and Respiratory Syncytial Virus Infection Among Full-Term Infants.

JAMA Netw Open
Jacobson KB, Watson AJ, Liao LD, Stephens SC, Merchant M, Zerbo O, Klein NP.   +6 more
europepmc   +1 more source

Real-World Effectiveness of Nirsevimab Against RSV-LRTI and Bronchiolitis Hospitalization: Results from the 2024-2025 Italian Universal Immunization Campaign in Newborns. [PDF]

Viruses
Auriti C, Gizzi C, Riccò M, Bellù R, Giuffrè M, Fabiano A, Cacace C, Cavicchioli P, Cuttano A, Valerio SD, Germini C, Napolitano M, Paviotti G, Peila C, Perrone S, Pesce S, Scarpelli G, Scutti G, Spanedda G, Staffler A, Agosti M, On Behalf Of The Italian Working Group On Rsv Prophylaxis Of Italian Society Of Neonatology.   +21 more
europepmc   +1 more source

Comment on Kura et al. Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States. <i>Vaccines</i> 2026, <i>14</i>, 411. [PDF]

Vaccines (Basel)
Hodges EN, Ghemmouri M, Neary MP, Gabriel V, Ottaviano C, Mari K, Ottobrino V, Chit A, Domachowske J, Yarnoff B, Musci R, Krilov LR.   +11 more
europepmc   +1 more source

Respiratory Pathogen Co-Detection in Hospitalized Infants with Bronchiolitis and Implementation of Universal Nirsevimab Immunoprophylaxis: A Six-Year Observational Study. [PDF]

Children (Basel)
Serra G, Martorana C, Barbera G, Catania M, Cipolla D, Colomba C, Farruggia P, Giuffrè M, La Malfa G, Greco M, Corsello G.   +10 more
europepmc   +1 more source

Regional inequality in infant RSV morbidity and mortality burden in the era of expanded RSV passive immunisation: a global projection modelling study. [PDF]

EClinicalMedicine
Ren S, Cong B, Zou J, Guo L, Nair H, Sparrow E, Feikin DR, Li Y.   +7 more
europepmc   +1 more source

Detection of nirsevimab-resistant RSV-B variants in children carrying the F:N201T substitution through genomic surveillance, Spain, 2025/26 season. [PDF]

Euro Surveill
Iglesias-Caballero M, Infantes JA, Campoy A, Camarero-Serrano S, Moreno S, Cano O, Vallejo-Palma G, González-Velasco C, Gaona C, Camacho-Martinez P, Merino-Diaz L, Vázquez-Morón S, Pozo F, Lepe JA, Mas V, Casas I.   +15 more
europepmc   +1 more source

Estimating and Projecting Efficacy of Monoclonal Antibodies Against Respiratory Syncytial Virus Beyond Clinical Trial Periods. [PDF]

Vaccines (Basel)
Wang D, Lang JC, Kura K, Chen YH.
europepmc   +1 more source

Respiratory Syncytial Virus-Related Hospitalizations Among Infants Receiving Nirsevimab.

JAMA Netw Open
Buchan SA, Xie J, Bhatt M, Papenburg J, Goldfarb DM, Pernica JM, Burstein B, Gravel J, Berthelot S, Kam AJ, Poonai N, Eltorki M, Finkelstein Y, Sabhaney V, Cheng J, Gill PJ, Dickinson JA, Kwong JC, Freedman SB, SPRINT-KIDS Project Team.   +19 more
europepmc   +1 more source

Acute viral bronchiolitis before and after implementation of <i>nirsevimab</i> prophylaxis in Italy: a multicentre retrospective cohort study. [PDF]

Lancet Reg Health Eur
Spatuzzo M, Corsello A, Riccò M, Bonci E, Di Francesco D, Strati MF, Amodio G, Manzalini R, Costantini E, Mazzotti S, Renni M, Coralluzzo F, Langone L, Fiumicelli E, Albonico G, Adornato S, Passarella V, Piras A, Forcucci F, Capuano MC, Basile A, Albini M, Cafforio A, Coppola C, Palmoni M, Bertolucci G, Bertolo S, Di Febo C, Donato A, Di Pasquale G, Toscano F, Tolfa G, Arpinelli M, Marseglia GL, Agostiniani R, Midulla F, ONSP-RSV Study Group.   +36 more
europepmc   +1 more source